Board of Directors

Axel Bolte currently serves as an investment advisor to HBM Partners AG, based in Zug/Switzerland. He has 16 years of experience in healthcare venture capital. Mr. Bolte was an investment manager at NMT New Medical Technologies AG, the first Swiss healthcare-focused venture capital firm. Since joining the private equity team at HBM Partners in 2003, he has led multiple biopharma investments. Previously, Mr. Bolte held a position in R&D management at Serono SA, Geneva.

He currently serves or has served on the board of directors of various private and public biotechnology companies, including Adnexus Therapeutics (acquired by BMS), Kolltan Pharmaceuticals, Nabriva Therapeutics, Newron Pharmaceuticals, and PTC Therapeutics.

Mr. Bolte studied biochemistry and organic chemistry at the University of Cambridge, United Kingdom and the Swiss Federal Institute of Technology in Zurich, Switzerland, where he obtained an M.S. in biochemistry. He also obtained an MBA from the University of St. Gallen, Switzerland.

Thomas Dyrberg, M.D., DMSc. serves as a Senior Partner of Novo Ventures, Novo A/S. He previously held research positions at the Hagedorn Research Institute in Gentofte, Denmark and at the Scripps Research Institute in La Jolla, Calif., and has published several articles within the fields of diabetes, immunology and autoimmunity. Dr. Dyrberg has also worked for Novo
Nordisk A/S in health care discovery and clinical drug development.

He currently serves or has served on the board of directors of several biotechnology companies, including Veloxis Pharmaceuticals A/S, Gloucester Pharmaceuticals, Inc., Allocure Inc., Lux Biosciences, Inc., Sapphire Therapeutics Inc., Delenex Therapeutics AG, and BioMimetic Therapeutics, Inc.

Dr. Dyrberg received his M.D. degree from the University of Copenhagen in 1981 and his Doctor of Medical Science (D.M.Sc.) degree, also from the University of Copenhagen, in 1986.

David Guyer, M.D. is a Co-Founder and Executive Chairman of the board of directors of Ophthotech Corporation. Dr. Guyer previously worked as a venture capitalist and Partner at SV Life Sciences. He has significant medical, drug development and commercial experience in ophthalmology.

Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings over $400 million, and oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for wet AMD. Under his leadership, Eyetech reached a peak market capitalization of approximately $2 billion.

Dr. Guyer received his Bachelor of Science (B.S.) degree from Yale College summa cum laude and his medical degree (M.D.) from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

David Redlick recently retired as a Partner in the Corporate Practice Group at Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale), an international law firm. Mr. Redlick joined WilmerHale in 1975 and has served as the co-chair of the Life Sciences Group, the co-chair of the Corporate Department and a member of the firm’s Executive Committee. Mr. Redlick’s legal practice focused on corporate and securities law, with an emphasis on public offerings, mergers and acquisitions, venture capital transactions and corporate collaborations. For over 40 years, Mr. Redlick served as counsel for a broad range of clients, including public and private life sciences and high technology companies, investment banks, venture capital funds and real estate development and finance companies. Mr. Redlick also currently serves as a special advisor at Leerink Partners LLC, an investment bank focused exclusively on the healthcare industry.

Michael Ross, Ph.D. serves as a Managing Partner of SV Life Sciences (SVLS). He was the tenth employee at Genentech, where he worked for 13 years in various roles including team leader and Vice President of Development. Dr. Ross also started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. He was the founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Novocell) and was also Managing Partner at Didyma, LLC, a biotechnology management consulting firm.

Dr. Ross currently serves or has served on the board of directors of several biotechnology companies, including Aderis Pharmaceuticals, Adimab, Alinea, Archemix, Arris Pharmaceuticals, Arsanis, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, Ikano, Itero Biopharmaceuticals, Link Medicine, MetaXen, Mpex, NKT Therapeutics, Rempex, Rinat, Sutro Biopharmaceuticals and Xenova. He also serves on the board of directors of Thayer School of Engineering at Dartmouth College.

Dr. Ross received his Bachelor of Arts (B.A.) from Dartmouth College, his Doctor of Philosophy (Ph.D.) degree in Chemistry from the California Institute of Technology (Caltech), and completed a Post-Doctorate program in Molecular Biology at Harvard University.

Glenn Sblendorio, M.B.A., is President and Chief Executive Officer of Ophthotech Corporation. He joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. Mr. Sblendorio also served as a member of the Board of Directors of Ophthotech from 2013 to 2016. Prior to joining Ophthotech, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BBA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.